文献速递脊柱脊髓外科神经肿瘤

手术治疗的症状性脊柱转移瘤患者报告与临床结局:脊柱肿瘤流行病学、诊疗过程与结局(EPOSO)前瞻性多机构国际研究结果

Patient-Reported and Clinical Outcomes of Surgically Treated Patients With Symptomatic Spinal Metastases: Results From Epidemiology, Process, and Outcomes of Spine Oncology (EPOSO), a Prospective, Multi-Institutional and International Study.
PubMed 文献 · Neurosurgery · 2024-06-04

EPOSO前瞻性观察队列纳入北美和欧洲10个专科中心280例接受手术的脊柱转移瘤患者,评估脊柱肿瘤特异性与通用患者报告结局。术后中位总生存501天,2年无进展生存率38.4%,与基线相比在6周至2年多个随访点健康相关生活质量显著且持久改善。

要点

  • 术后中位总生存501天,2年无进展生存率38.4%。
  • 与基线相比,6周至2年多个随访点健康相关生活质量显著且持久改善。
  • 89.6%患者脊柱肿瘤不稳定评分≥7分,47.2%为高级别硬膜外脊髓压迫(2-3级)。

核心结论

  • 多机构前瞻性结局数据证实,手术减压和/或稳定为转移性脊柱疾病患者提供多个健康相关生活质量领域的显著且持久改善,包括基于脊柱肿瘤研究组结局问卷v2.0的脊柱特异性结局。

研究设计与样本

  • EPOSO(ClinicalTrials.gov标识符NCT01825161)为前瞻性观察队列研究,纳入北美和欧洲10个专科中心。
  • 纳入18至75岁接受脊柱转移瘤手术的患者,前瞻性评估脊柱肿瘤特异性与通用患者报告结局工具,采集至少2年或直至死亡。
  • 共纳入280例患者(51.8%女性,平均年龄57.9岁)。

主要发现

  • 初诊时平均Charlson合并症指数为6.0,35.7%根据美国脊髓损伤协会评分有神经功能缺损,47.2%为高级别硬膜外脊髓压迫(2-3级),89.6%脊柱肿瘤不稳定评分为≥7分(即将发生或明显不稳定)。
  • 最常见原发肿瘤部位为乳腺(20.2%)、肺(18.8%)、肾(16.2%)和前列腺(6.5%)。
  • 术后中位总生存501天,2年无进展生存率38.4%。
  • 与基线相比,在6周、12周、26周、1年和2年随访评估中,包括脊柱肿瘤研究组结局问卷v2.0、简表36第2版、EuroQol-5维度(3L)和疼痛数字评定量表在内的一组患者报告结局问卷显示健康相关生活质量显著且持久改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The palliative impact of spine surgery for metastatic disease is evolving with improvements in surgical technique and multidisciplinary cancer care. The goal of this study was to prospectively evaluate long-term clinical outcomes including health-related quality-of-life (HRQOL) measures, using spine cancer-specific patient-reported-outcome (PRO) measures, in patients with symptomatic spinal metastases who underwent surgical management. METHODS: The Epidemiology, Process, and Outcomes of Spine Oncology (EPOSO, ClinicalTrials.gov identifier: NCT01825161) trial is a prospective-observational cohort study that included 10 specialist centers in North America and Europe. Patients aged 18 to 75 years who underwent surgery for spinal metastases were included. Prospective assessments included both spine tumor-specific and generic PRO tools which were collected for a minimum of 2 years post-treatment or until death. RESULTS: Two hundred and eighty patients (51.8% female, mean age 57.9 years) were included. At presentation, the mean Charlson Comorbidity Index was 6.0, 35.7% had neurological deficits as defined by the American Spinal Cord Injury Association scores, 47.2% had high-grade epidural spinal cord compression (2-3), and 89.6% had impending or frank instability as measured by a Spinal Instability Neoplastic Score of ≥7. The most common primary tumor sites were breast (20.2%), lung (18.8%), kidney (16.2%), and prostate (6.5%). The median overall survival postsurgery was 501 days, and the 2-year progression-free-survival rate was 38.4%. Compared with baseline, significant and durable improvements in HRQOL were observed at the 6-week, 12-week, 26-week, 1-year, and 2-year follow-up assessments from a battery of PRO questionnaires including the spine cancer-specific, validated, Spine Oncology Study Group Outcomes Questionnaire v2.0, the Short Form 36 version 2, EuroQol-5 Dimension (3L), and pain numerical rating scale score. CONCLUSION: Multi-institutional, prospective-outcomes data confirm that surgical decompression and/or stabilization provides meaningful and durable improvements in multiple HRQOL domains, including spine-specific outcomes based on the Spine Oncology Study Group Outcomes Questionnaire v2.0, for patients with metastatic spine disease.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Barzilai O, Sahgal A, Rhines LD, et al. Patient-Reported and Clinical Outcomes of Surgically Treated Patients With Symptomatic Spinal Metastases: Results From Epidemiology, Process, and Outcomes of Spine Oncology (EPOSO), a Prospective, Multi-Institutional and International Study. Neurosurgery. 2024. PMID: 38832791. doi:10.1227/neu.0000000000002989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。